IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Holdings Raised by Marshall Wace LLP

Marshall Wace LLP boosted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 23.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 312,666 shares of the company's stock after acquiring an additional 60,361 shares during the period. Marshall Wace LLP owned about 0.36% of IDEAYA Biosciences worth $8,036,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Jump Financial LLC lifted its holdings in IDEAYA Biosciences by 64.5% in the fourth quarter. Jump Financial LLC now owns 114,902 shares of the company's stock worth $2,953,000 after acquiring an additional 45,035 shares during the last quarter. Guggenheim Capital LLC bought a new position in IDEAYA Biosciences in the fourth quarter worth about $807,000. XTX Topco Ltd lifted its holdings in IDEAYA Biosciences by 64.3% in the fourth quarter. XTX Topco Ltd now owns 12,679 shares of the company's stock worth $326,000 after acquiring an additional 4,960 shares during the last quarter. Mariner LLC lifted its holdings in IDEAYA Biosciences by 9.8% in the fourth quarter. Mariner LLC now owns 9,775 shares of the company's stock worth $251,000 after acquiring an additional 869 shares during the last quarter. Finally, Barclays PLC lifted its holdings in IDEAYA Biosciences by 9.7% in the fourth quarter. Barclays PLC now owns 198,756 shares of the company's stock worth $5,108,000 after acquiring an additional 17,586 shares during the last quarter. Institutional investors own 98.29% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Royal Bank of Canada reaffirmed an "outperform" rating and set a $61.00 price target on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Stephens reaffirmed an "overweight" rating and set a $50.00 price target on shares of IDEAYA Biosciences in a report on Friday, February 14th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Two analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $53.58.

IDEAYA Biosciences Trading Up 3.9 %

IDYA stock traded up $0.75 during trading hours on Monday, hitting $19.75. 2,221,660 shares of the stock traded hands, compared to its average volume of 959,881. The stock has a 50-day simple moving average of $17.98 and a 200 day simple moving average of $23.29. IDEAYA Biosciences, Inc. has a one year low of $13.45 and a one year high of $44.42. The company has a market cap of $1.73 billion, a P/E ratio of -5.98 and a beta of 0.51.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its earnings results on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The company had revenue of $7.00 million during the quarter, compared to analyst estimates of $7.00 million. Analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.